![](https://endpts.com/wp-content/uploads/2024/05/Robert-Blum-Cytokinetics-feature.jpg)
Robert Blum, Cytokinetics CEO
Cytokinetics lifts curtain on Phase 3 aficamten data, commercial launch prep underway
Cytokinetics detailed results on Monday from a late-stage trial of aficamten for a rare heart disease, and the company is already hiring medical affairs and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.